Skip to main content

Viking Global Investors — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

54
Companies
$2.4B
Total invested
$51.2M
Avg. check
63
Industries
Biotechnology 11Health Care 10Medical 6Therapeutics 5Software 4Health Diagnostics 3+57 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 54
Mediphage Bioceuticals
January 2026

Developing safe and effective gene delivery platforms to unlock the therapeutic power of personalized, redoseable genetic medicine.

Biotechnology · TorontoGrant
HI-Bio
January 2024

Human Immunology Biosciences is a biotechnology company that focuses on developing therapies for immune-mediated diseases.

Biotechnology · South San Francisco$95.0M Series B
Vector Biomed
December 2022

Vector Biomed is a state-of-the-art custom vector design and GMP manufacturing company.

Machinery Manufacturing · Gaithersburg$15.0M Venture - Series Unknown
Antheia
January 2026

Antheia uses synthetic biology to produce biosynthetic KSMs and APIs for essential medicines through engineered microbial fermentation.

Biotechnology · Menlo Park$24.0M Series C
Valsoft
December 2024

Valsoft specializes in the acquisition and growth of vertical-market software enterprises.

Business Development · Montréal$150.0M Private Equity
Xcell Biosciences
December 2024

Xcell Biosciences is a next-generation development and manufacturing platform for enhanced cell therapy performance.

Biotechnology · San Francisco$1.4M Undisclosed
Allonnia
December 2025

Allonnia is an environmental biotechnology company focused on metals and mining, plastics and PFAS, plus other emerging contaminants.

Biotechnology · Boston$20.0M Series A
Cognism
January 2022

Cognism is a B2B sales acceleration software company that provides a marketing and sales acceleration solution.

Analytics · London$87.8M Series C
Solarea Bio
November 2025

Solarea Bio develops microbial therapeutics aimed to treat indications derived from chronic inflammation to aid human health.

Biotechnology · Cambridge$9.9M Venture - Series Unknown
Arcaea
October 2021

Arcaea's mission is to build a new foundation for the beauty industry through expressive biology.

Beauty · Boston$78.0M Series A
Patina
October 2021

Patina is reinventing primary care for adults 65+ so everyone gets the healthcare and aging experience they deserve.

Health Care · Philadelphia$50.0M Series A
NextGen Jane
May 2025

NextGen Jane is a data-driven women's health company.

Biotechnology · Oakland$2.2M Grant
1Health
February 2025

1Health is a health platform that connects clinicians and patients to labs.

Health Care · San Francisco$1.8M Series Unknown
Humaneva
September 2024

Humaneva is a healthacare research company that offers reliable clinical research data that empowers the medical community.

Clinical Trials · Raleigh$50.0M Private Equity
MyForest Foods
February 2024

MyForest Foods grows meatless mycelium on vertical farms and supplies sustainable natural flagship products to consumers.

Alternative Protein · Albany$3.5M Series Unknown
Zentalis Pharmaceuticals
June 2023

Zentalis is a pharmaceutical company focused on developing clinical therapeutics for cancer patients.

Biopharma · New York$235.5M Post Ipo Equity
Dock
May 2022

Dock is a provider of a financial technology company that integrates card issuing and core banking services.

Credit Cards · São Paulo$110.0M Private Equity
Revenova
April 2022

Revenova is a provider of CRM-powered transportation management systems (TMS) for 3PLs, Freight Brokers, Carriers and Shippers

Cloud Computing · Chicago$63.0M Series Unknown
Astarte Medical
September 2021

Astarte Medical is clinical intelligence company providing digital solutions to support protocol-driven care across pediatric populations.

Analytics · Yardley$7.6M Series A
Resilient Biotics
January 2021

Resilient Biotics utilizes big data analytics to design microbiome-based therapeutics and advanced screening methods.

Analytics · Raleigh$7.2M Series A
MedAnswers
August 2019

A health tech company disrupting how those struggling to conceive access specialty fertility care through the best of science and tech.

Android · Washington$5.0M Seed
Joyn Bio
September 2017

A joint venture founded by Bayer and Ginkgo Bioworks developing probiotics for plants.

Agriculture · Boston$100.0M Series A
Vitagene
September 2017

The world's First and Only Personalization Platform for Health and Wellness Products and Services Tailored to Your DNA and Lifestyle.

Data Mining · San FranciscoSeed

Where Viking Global Investors invests

Biotechnology11
Health Care10
Medical6
Therapeutics5
Software4
Health Diagnostics3

About Viking Global Investors's portfolio

How many companies has Viking Global Investors invested in?

Viking Global Investors has invested in 54 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Viking Global Investors invest in?

Viking Global Investors's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Software. The firm invests across 63 different industry categories.

What is Viking Global Investors's largest investment?

Among tracked funding rounds, Zentalis Pharmaceuticals received $235.5M in a Post Ipo Equity round. Viking Global Investors's total known invested capital is $2.4B.

What is the average investment size for Viking Global Investors?

Viking Global Investors's average investment size is $51.2M across its portfolio of 54 companies.

What are Viking Global Investors's most recent investments?

Recent Viking Global Investors portfolio additions include Mediphage Bioceuticals, HI-Bio, Vector Biomed, Antheia, Valsoft. These companies were founded in 2020 or later.

Reach the founders behind these 54 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →